Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

4.590 +0.160 (+3.61%)
Streaming Delayed Price Updated: 10:26 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jasper Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 Next >
Russell 2000 Index Forecast As The Crash Continues: Buy The Dip?
The Russell 2000 Index has plunged and formed a death cross this year as American stocks sink amid rising worries about Donald Trump’s policies. 
Via Talk Markets
Topics Government Stocks / Equities
Exposures Political
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Crude Oil Down 1%; US Weekly Jobless Claims Decline
Via Benzinga
Exposures Fossil Fuels
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025. 
Via Benzinga
US Stocks Down; Acuity Brands Posts Weak Revenue
Via Benzinga
JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips 
Via InvestorPlace
Jasper Therapeutics: Q3 Earnings Insights
Via Benzinga
Where Jasper Therapeutics Stands With Analysts
Via Benzinga
Futures Slump As Yields, Dollar Soar
In premarket trading Quantum stocks tumbled after Nvidia CEO Jensen Huang said that “very useful” quantum computers are likely decades away. 
Via Talk Markets
Topics Commodities Stocks / Equities
Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?
Jasper Therapeutics' SPOTLIGHT study reports 93% clinical response in cold urticaria and symptomatic dermographism. The 120mg dose showed 83% complete response and no severe adverse events. Full data... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Jasper Therapeutics: Q1 Earnings Insights
Via Benzinga
JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q2 2024
JSPR stock results show that Jasper Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q1 2024
JSPR stock results show that Jasper Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Via Benzinga
Over $15M Bet On Aon? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
Via Benzinga
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
Jasper Therapeutics, Inc. (NASDAQ: JSPR) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
$4M Bet On Jasper Therapeutics? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by around 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) jumped 119.6% to $1.96 in pre-market trading. HeartCore forged an agreement with rYojbaba Inc for its tenth Go IPO consulting service win. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.